CellResearch Corporation

Last updated
CellResearch Corporation
Industry Biotechnology, Stem Cell Technology
Founded2002
FoundersPhan Toan Thang (CSO), Gavin Tan (CEO), Ivor Lim (CMO)
Headquarters
Singapore
ProductsSkin care, Cosmetics, Cord Tissue banking
Website cellresearchcorp.com

CellResearch Corporation is a biotechnology company with a primary focus on skin cell and cord lining stem cell research. [1] CellResearch has one of the world's largest private skin-, scar-, and keloid-cell libraries which have been used for research by cell culture laboratories worldwide, including those at Harvard University, Procter & Gamble and Johnson & Johnson. [2] It owns 39 patents worldwide with intellectual property for the isolation of stem cells from the umbilical cord lining membrane of all mammals, which also includes the banking and cultivation of these cells, as well as the therapeutic applications of these cells. [2] [3]

Contents

The firm was founded in 2002 by Phan Toan Thang, Ivor Lim and Gavin Tan and originally sold skin cell samples for research. [3] [1] In 2014, it was reported that the company was worth $640 million. [3]

Operations

In 2004, Phan found two unique kinds of stem cells from the outer lining membrane of the umbilical cord. [4] The umbilical cord lining can yield 6 billion epithelial and 6 billion mesenchymal stem cells from a primary explant in one generation. In comparison, the bone marrow produces a few million mesenchymal stem cells per bone marrow aspiration. [3]

Initial studies focused on wound healing. [1] [2] In 2015, the firm began developing current Good Manufacturing Practice (cGMP) grade cord lining mesenchymal stem cells, which could be used for human transplantation. The stem cell product, called CorLiCyte, was approved for a USFDA trial to heal diabetic wounds, to be completed around 2018-2019. [5] [3] The firm also developed the skincare product CALECIM, made from red deer umbilical cord lining extract, which comprises secreted cell proteins integrated into a cream and serum cosmetic product. [1] [2]

CordLabs licenses its proprietary cord lining stem cell storage technology to cord blood banks, allowing them to also bank cord tissue from which the cord lining stem cells are derived. [3]

Related Research Articles

Bone marrow

Bone marrow is a semi-solid tissue found within the spongy or cancellous portions of bones. In birds and mammals, bone marrow is the primary site of new blood cell production or haematopoiesis. It is composed of hematopoietic cells, marrow adipose tissue, and supportive stromal cells. In adult humans, bone marrow is primarily located in the ribs, vertebrae, sternum, and bones of the pelvis. Bone marrow comprises approximately 5% of total body mass in healthy adult humans, such that a man weighing 73 kg will have around 3.65 kg of bone marrow.

Umbilical cord

In placental mammals, the umbilical cord is a conduit between the developing embryo or fetus and the placenta. During prenatal development, the umbilical cord is physiologically and genetically part of the fetus and normally contains two arteries and one vein, buried within Wharton's jelly. The umbilical vein supplies the fetus with oxygenated, nutrient-rich blood from the placenta. Conversely, the fetal heart pumps low oxygen containing blood, nutrient-depleted blood through the umbilical arteries back to the placenta.

Tissue engineering

Tissue engineering is a biomedical engineering discipline that uses a combination of cells, engineering, materials methods, and suitable biochemical and physicochemical factors to restore, maintain, improve, or replace different types of biological tissues. Tissue engineering often involves the use of cells placed on tissue scaffolds in the formation of new viable tissue for a medical purpose but is not limited to applications involving cells and tissue scaffolds. While it was once categorized as a sub-field of biomaterials, having grown in scope and importance it can be considered as a field in its own.

Hematopoietic stem cell transplantation Medical procedure to replace blood or immune stem cells

Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood. It may be autologous, allogeneic or syngeneic.

Graft-versus-host disease

Graft-versus-host disease (GvHD) is a syndrome, characterized by inflammation in different organs, with the specificity of epithelial cell apoptosis and crypt drop out. GvHD is commonly associated with bone marrow transplants and stem cell transplants. GvHD also applies to other forms of transplanted tissues such as solid organ transplants.

A cord blood bank is a facility which stores umbilical cord blood for future use. Both private and public cord blood banks have developed in response to the potential for cord blood in treating diseases of the blood and immune systems. Public cord blood banks accept donations to be used for anyone in need, and as such function like public blood banks. Traditionally, public cord blood banking has been more widely accepted by the medical community. Private cord blood banks store cord blood solely for potential use by the donor or donor's family. Private banks typically charge around $2,000 for the collection and around $200 a year for storage.

Wharton's jelly is a gelatinous substance within the umbilical cord, largely made up of mucopolysaccharides. It acts as a mucous connective tissue containing some fibroblasts and macrophages, and is derived from extra-embryonic mesoderm.

Regenerative medicine Field of medicine involved in regenerating tissues

Regenerative medicine deals with the "process of replacing, engineering or regenerating human or animal cells, tissues or organs to restore or establish normal function". This field holds the promise of engineering damaged tissues and organs by stimulating the body's own repair mechanisms to functionally heal previously irreparable tissues or organs.

Cord blood is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders such as cancer.

Stromal cells, or mesenchymal stromal cells, are differentiating cells found in abundance within bone marrow but can also be seen all around the body. Stromal cells can become connective tissue cells of any organ, for example in the uterine mucosa (endometrium), prostate, bone marrow, lymph node and the ovary. They are cells that support the function of the parenchymal cells of that organ. The most common stromal cells include fibroblasts and pericytes. The term stromal comes from Latin stromat-, "bed covering", and Ancient Greek στρῶμα, strôma, "bed".

Adult stem cell Multipotent stem cell in the adult body

Adult stem cells are undifferentiated cells, found throughout the body after development, that multiply by cell division to replenish dying cells and regenerate damaged tissues. Also known as somatic stem cells , they can be found in juvenile as well as adult animals and humans, unlike embryonic stem cells.

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. As of 2016, the only established therapy using stem cells is hematopoietic stem cell transplantation. This usually takes the form of a bone-marrow transplantation, but the cells can also be derived from umbilical cord blood. Research is underway to develop various sources for stem cells as well as to apply stem-cell treatments for neurodegenerative diseases and conditions such as diabetes and heart disease.

The National Marrow Donor Program (NMDP) is a nonprofit organization founded in 1986 and based in Minneapolis, Minnesota, that operates the Be The Match Registry of volunteer hematopoietic cell donors and umbilical cord blood units in the United States.

HAS1

Hyaluronan synthase 1 is an enzyme that in humans is encoded by the HAS1 gene.

Mesenchymal stem cell Multipotent, non-hematopoietic adult stem cells present in multiple tissues

Mesenchymal stem cells (MSCs) also known as mesenchymal stromal cells or medicinal signaling cells are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes and adipocytes.

Adult mesenchymal stem cells (MSCs) are being used by researchers in the fields of regenerative medicine and tissue engineering, to artificially reconstruct human tissue which has been previously damaged. Mesenchymal stem cells have the capacity to become any type of fully developed cell, which can contribute to replacing muscle tissues or internal organs. To help discover the therapeutic uses of these stem cells they are grown in laboratories or by using medication to stimulate new cell growth within the human body. In MSC therapy the cells are extracted from the adult patient’s bone marrow via a procedure called bone marrow aspiration. This usually involves inserting a needle into the back of the patients hip bone and removing the sample from there. These cells are then grown under controlled in vitro conditions in a lab, so that they can multiply and same time mature( also referred to as differentiated. This process may take two to three weeks. The kind of mature, fully differentiated cell phenotype and the number of those cells created though this can be influenced in three ways. Firstly by varying the initial seed density in the culture medium, secondly through changing the conditions of the medium during expansion, and lastly through the addition of additives such as proteins or growth hormones to the culture medium. They are then harvested and put back into the patient through local delivery or systemic infusion.

Dermal fibroblasts are cells within the dermis layer of skin which are responsible for generating connective tissue and allowing the skin to recover from injury. Using organelles, dermal fibroblasts generate and maintain the connective tissue which unites separate cell layers. Furthermore, these dermal fibroblasts produce the protein molecules including laminin and fibronectin which comprise the extracellular matrix. By creating the extracellular matrix between the dermis and epidermis, fibroblasts allow the epithelial cells of the epidermis to affix the matrix, thereby allowing the epidermal cells to effectively join together to form the top layer of the skin.

A Muse cell is an endogenous non-cancerous pluripotent stem cell. They reside in the connective tissue of nearly every organ, bone marrow and peripheral blood. They are collectable from commercially obtainable mesenchymal cells such as human fibroblasts, bone marrow-mesenchymal stem cells and adipose-derived stem cells. Muse cells are able to generate cells representative of all three germ layers from a single cell both spontaneously and under cytokine induction. Expression of pluripotency genes and triploblastic differentiation are self-renewable over generations. Muse cells do not undergo teratoma formation when transplanted into a host environment in vivo. This can be explained in part by their intrinsically low telomerase activity, eradicating the risk of tumorigenesis through unbridled cell proliferation. They were discovered in 2010 by Mari Dezawa and her research group. Clinical trials for acute myocardial infarction, stroke, epidermolysis bullosa and spinal cord injury are conducted by Life Science Institute, Inc., a group company of Mitsubishi Chemical Holdings company.

Cord lining, cord tissue, or umbilical cord lining membrane, is the outermost layer of the umbilical cord. As the umbilical cord itself is an extension of the placenta, the umbilical cord lining membrane is an extension of the amniotic membrane covering the placenta. The umbilical cord lining membrane comprises two layers: the amniotic layer and the sub-amniotic layer. The umbilical cord lining membrane is a rich source of two strains of stem cells (CLSCs): epithelial stem cells (CLECs) and mesenchymal stem cells (CLMCs). Discovered by Singapore-based CellResearch Corporation in 2004, this is the best known source for harvesting human stem cells.

Cordlife

Incorporated in May 2001, Cordlife Group Limited, is a consumer health company and one of the leading providers of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.

References

  1. 1 2 3 4 Grace Chng (August 13, 2015). "Stem cell skincare product goes global". Straits Times. Retrieved January 8, 2017.
  2. 1 2 3 4 Gladys Chung (December 24, 2015). "Beauty brand scores with stem cells". The Straits Times. Retrieved January 8, 2017.
  3. 1 2 3 4 5 6 Karen Tee (May 5, 2016). "The Peak Interview:CellResearch Corp CEO Gavin Tan Intends To Heal The World". The Peak. Retrieved January 8, 2017.
  4. Jalelah Abu Baker (June 20, 2016). "Doctor's fascination with wound healing turns into a $700m biotech company". Straits Times. Retrieved January 8, 2017.
  5. Samantha Boh (November 25, 2016). "FDA trial for S'pore biomedical company". Straits Times. Retrieved January 8, 2017.

Further reading